Skip to content
lifestyle.trondstidkontroll.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Apnimed, Inc.
Apnimed Announces Pricing of Upsized Initial Public Offering
July 30, 2026
Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA)
July 14, 2026
Apnimed Strengthens Leadership Team with Appointments of Industry Veterans Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs
July 1, 2026
Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
June 10, 2026
Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy
June 8, 2026